Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.38 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.38 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.38 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.38 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.38 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834917 | 0.90 | LMNA (0.41) | NAAAFPR2PROKR1PKMSMN1; SMN2 | |
| SCHEMBL2834671 | 0.84 | FPR2 (0.36) | NAAACACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL2360732 | 0.78 | BDKRB1 (0.40) | NAAAHCRTR1HCRTR2 | |
| SCHEMBL2364339 | 0.77 | CYP2D6 (0.42) | NAAAHCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL2835037 | 0.77 | CHRM4 (0.36) | NAAAFPR2PROKR1HCRTR1HCRTR2 | |
| SCHEMBL14715495 | 0.76 | KDM4E (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL2836034 | 0.75 | LMNA (0.44) | NAAAPKMSMN1; SMN2 | |
| SCHEMBL2831995 | 0.75 | LMNA (0.40) | FPR2PROKR1PKMSMN1; SMN2 | |
| SCHEMBL2830936 | 0.74 | ALDH1A1 (0.40) | — | |
| SCHEMBL2839849 | 0.74 | CASP3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | ADORA2B, CCNB1, TYMS | NAAA 1814/4885CACNB4 2479/4885CACNA1A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.